Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 24, 2012

 

 

CHEMOCENTRYX, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-35420   94-3254365

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

850 Maude Avenue, Mountain View, CA   94043
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (650) 210-2900

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.02. Compensatory Arrangements of Certain Officers.

On July 24, 2012, the Compensation Committee of the Board of Directors (the “Committee”) of ChemoCentryx, Inc. (the “Company”) approved and awarded stock options to the executive officers listed below (the “Named Executive Officers”) under the Company’s 2012 Equity Incentive Award Plan. The exercise price per share of such stock options is $14.31, the closing price per share of the Company’s common stock on July 24, 2012. Twenty-five percent of the total number of shares of common stock subject to each Named Executive Officer’s option will vest on July 1, 2013, and 1/48th of the total number of shares of common stock subject to such option will vest monthly thereafter, subject to such Named Executive Officer’s continued employment or service relationship with the Company on each such vesting date.

The stock options are as follows:

 

Name    Title    Stock Options

Thomas J. Schall, Ph.D.

   President and Chief Executive
Officer
   485,088

Markus J. Cappel, Ph.D.

   Chief Business Officer and Treasurer    123,156

Susan M. Kanaya

   Senior Vice President, Finance, Chief
Financial Officer and Secretary
   121,166

Juan C. Jaen, Ph.D.

   Senior Vice President, Drug
Discovery and Chief Scientific
Officer
   110,664

Petrus Bekker, M.D., Ph.D.

   Senior Vice President of Medical and
Clinical Affairs
   104,289


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CHEMOCENTRYX, INC.
Date: July 27, 2012      
    By:  

/s/ Susan M. Kanaya

    Name:   Susan M. Kanaya
    Title:  

Senior Vice President, Finance, Chief Financial

Officer and Secretary